News

Here you can read all news about stem cells.

Learn More

Diseases that we treat

Primary Progressive Multiple Sclerosis (PPMS)

27 Jan 2020

Introduction
Basic Characteristics of the Primary Progressive Multiple Sclerosis
Treatment with Disease-Modifying Drugs
Symptom Management and Rehabilitation
Stem Cell-Based Approach in PPMS Therapy
Main Features of MSCs
MSC-Based Treatment Procedure
Additional Therapies
List of References

Introduction

Multiple sclerosis (MS) is a life-long autoimmune disease affecting the central nervous system (the brain and spinal cord) and is the most frequent cause of non-traumatic neurological disability among young adults [1]. In MS, cells of the immune system attack neurons and destroy myelin, a protective insulating layer of the nerve fibers. This affects the proper transmission of nerve electrical signals and causes the symptoms of the disease. Loss of oligodendrocytes, myelin producing cells in the central nervous system, also contributes to disease progression [2].

This video demonstrates the properties of nerve cells and the changes that occur in MS [3]:

In most forms of MS, periods of active symptoms are followed by periods of remission. During periods when the disease is active and the patient is experiencing symptoms, new active inflammatory lesions form which leads to further progression of the disease, expressed as worsening neurologic function and resulting in an accumulation of disabilities. In primary progressive MS (PPMS), there are no expressed relapses and inflammation is less pronounced. That is why most disease modifying drugs do not work in PPMS since the drugs are aimed at decreasing inflammation via modulation of the immune system [4].

When finding treatment options for patients with PPMS, researchers focus on neuroprotection and reparation of tissue damage. Neuroprotection defends the axons from damage and stops or slows further disease progression. Strategies that promote remyelination and regeneration help to stimulate recovery and the repair of damaged axons.

With our current knowledge of stem cell properties, efficacy and safety, the cell-based approach can be used as a treatment for patients with PPMS.

Basic Characteristics of the Primary Progressive Multiple Sclerosis

PPMS is a part of the spectrum of progressive MS types. Patients with PPMS do not have acute attacks (relapses) and periods of remissions. Their symptoms progress gradually, and functional ability steadily worsens over time.

The graphic demonstrates changes in disease activity over time in PPMS

Figure 1. The graphic demonstrates changes in disease activity over time in PPMS [5].

This type of MS occurs in only 10%–15% of people with MS. The majority of people with primary progressive MS are diagnosed in their 40s and 50s [6].

PPMS is characterized by prevalent lesions in the spinal cord, which is expressed in stiffness and/or weakness in the legs and problems with walking. By contrast to relapsing forms of MS, the level of inflammation is lesser in PPMS. Inflammation in MS is a complex reaction by which the immune system responds to damage to the neuron-covering myelin. In PPMS, nerves themselves are more damaged compared with other types of MS.

This causes a constant progression of the disease and, at the same time, low susceptibility to drugs that are used for the treatment of other forms of multiple sclerosis.

Treatment with Disease-Modifying Drugs

Unlike other types of MS which can be managed by an array of disease-modifying treatments (DMTs) with several mechanisms of action, the only treatment option for PPMS approved by the FDA and authorization agencies in other countries is ocrelizumab. It demonstrated the capacity to slow disability progression in some people with early PPMS in one clinical trial. However, treatment efficacy may wane when a person is treated for a long time [7]. The drug is administered as intravenous infusions every six months.

Ocrelizumab binds to specific immune cells that provoke the immune system to attack the myelin around neurons. Due to suppression of the immune system, patients treated with ocrelizumab have been observed to experience increased levels of infections, including hepatitis B [8].

While rare, serious adverse reactions have been associated with ocrelizumab including malignancies and progressive multifocal leukoencephalopathy (PML). PML is a brain infection caused by activated JC virus (or John Cunningham virus, or Human polyomavirus 2). Its typical symptoms quickly progress and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

Symptom Management and Rehabilitation

Physical activity is an essential part of comprehensive care for PPMS. Exercises, stretching and physical therapy help to improve the most common symptoms of multiple sclerosis, such as:

as well as being able to help improve and stabilize the patient’s mood [9, 10].

Physical activity regulates the immune system on the cellular level and reduces inflammation [11, 12, 13, 14, 15]. Together with basic treatment, it allows patients to maintain a certain level of mobility, independence, productivity and emotional well-being despite the MS.

For some symptoms, proper medications recommended by a physician may be required.

Stem Cell-Based Approach in PPMS Therapy

Stem cell-based therapies have been researched and developed for about 2 decades. They are used as an alternative or complementary approach to find an effective way to block MS progression and repair neural damage. The following types of stem cells are studied or already used for this purpose:

We are going to specifically focus on discussing multipotent mesenchymal stem cells (MSCs) due to their advantages as the most convenient cell product in terms of production and clinical use, as well as their safety and potential efficacy in MS management.

Main Features of MSCs

Potential neuroprotective and neurorestorative effects of MSCs mediated by secretion of biologically active molecules

Figure 2. Potential neuroprotective and neurorestorative effects of MSCs mediated by secretion of biologically active molecules [18].

A range of both pre-clinical data and clinical studies have shown that MSCs derived from various sources (bone marrow, fat tissue, placenta, etc.) act as immunomodulators [17]. MSCs are beneficial due to their neuroprotective properties and ability to promote remyelination, formation of new neurons and differentiation of neural progenitor cells into mature neurons, so that damaged neurons are replaced with new ones [19]. It was also shown that MSCs directly boost the differentiation of oligodendrocytes (cells of the central nervous system which produce myelin) [20, 21].

The above listed functions of MSCs are provided by soluble biologically active molecules, such as cytokines, chemokines and growth factors, released by this type of stem cell [22].

The studies involved different patient populations, cell products and routes of administration, all of which showed an overall favorable safety profile [17]. Larger trials aimed at confirming the efficacy are ongoing [23, 24, 25].

MSC-Based Treatment Procedure

The treatment procedure includes 4 steps:


  1. MSCs collection from patient’s bone marrow/adipose tissue (under local anesthesia) or from donated tissues, such as the placenta or umbilical cord (Wharton’s jelly). Thus, cells may be both donated or autologous (patient’s own).
  2. Processing and cultivation of harvested cells.
  3. Bioactivation of MSCs to obtain the optimal cell product.
  4. Local, intrathecal (into the spinal canal) and/or intravenous administration (through an IV Drip) of the prepared cell product.

When donor cell-based products are used, they can be introduced immediately because they are prepared beforehand.

Though the ability of stem cells to the potent treatment of certain diseases has been proven, they cannot be considered as a guaranteed cure for all patients. The effectiveness of the therapy depends on multiple factors: diagnosis, initial condition, stage of the illness, the severity of symptoms, age of the patient, hereditary predisposition, lifestyle, etc. Also, applying only stem cells for some cases may be not enough. Cell therapy works more effectively when combined with other therapeutic methods that help activate the tissue repair process.

Additional Therapies

The treatment plan is personalized for each patient depending on the duration of the disease, concomitant conditions and general status of the patient. The following procedures are advised for all patients with MS, including PPMS, in addition to basic treatment with MSCs:

as well as others.

Instrument for Mesodiencephalic modulation (MDM)

Figure 3. Instrument for Mesodiencephalic modulation (MDM). It affects the central nervous system via an impulse current of a specific frequency, promoting the recovery processes and relieving pain.

These procedures contribute to the regeneration process, activated with the help of injected stem cells, as well as alleviating symptoms and improving mobility and overall well-being of the patient.

Learn more about intended results of multiple sclerosis therapy with stem cells >>>

– Published on January 27, 2020

by Swiss Medica team

List of References

  1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221–31.
  2. Jadasz JJ et al. The remyelination Philosopher’s Stone: stem and progenitor cell therapies for multiple sclerosis. Cell Tissue Res. 2012 Jul;349(1):331-47.
  3. Multiple Sclerosis Trust, UK.
  4. Ciotti JR and Cross AH. Disease-Modifying Treatment in Progressive Multiple Sclerosis. Curr Treat Options Neurol. 2018 Apr 7;20(5):12.
  5. National MS Society.
  6. Multiple Sclerosis Trust, UK.
  7. Guidance of the National Institute for Health and Care Excellence, UK.
  8. FDA-approved prescribing information for OCREVUS ™ (ocrelizumab).
  9. Döring A et al. Exercise in multiple sclerosis — an integral component of disease management. EPMA J. 2012; 3(1): 2.
  10. Barry A at al. Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology. Front Physiol. 2016; 7:194.
  11. White LJ, Dressendorfer RH. Exercise and multiple sclerosis. Sports Med. 2004; 34(15):1077-100.
  12. Gleeson M. Immune function in sport and exercise. J Appl Physiol (1985). 2007 Aug; 103(2):693-9.
  13. White LJ, Castellano V. Exercise and brain health—implications for multiple sclerosis: Part II—immune factors and stress hormones. Sports Med. 2008; 38(3):179-86.
  14. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol (1985). 2005 Apr; 98(4):1154-62.
  15. Florindo M. Inflammatory cytokines and physical activity in multiple sclerosis. ISRN Neurol. 2014; 2014:151572.
  16. Cuascut FX, Hutton GJ. Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives. Biomedicines. 2019 Mar 30;7(2).
  17. Scolding NJ et al. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017 Nov; 140(11): 2776–2796.
  18. Castillo-Melendez M et al. Stem cell therapy to protect and repair the developing brain: a review of mechanisms of action of cord blood and amnion epithelial derived cells. Front Neurosci. 2013; 7: 194.
  19. Laroni A, de Rosbo NK and Uccelli A. (2015). Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. Immunol Lett. 2015;168:183–190.
  20. Rivera FJ, Aigner L. Adult mesenchymal stem cell therapy for myelin repair in multiple sclerosis. Biol Res. 2012;45(3):257-68.
  21. Bai L et al. Hepatocyte growth factor mediates mesenchymal stem cell‐induced recovery in multiple sclerosis models. 2012. Nature Neuroscience, 15(6), 862–870.
  22. Zhou Y et al. The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity. J Clin Med. 2019 Jul; 8(7): 1025.
  23. Rice C et al. Assessment of bone marrow-derived cellular therapy in progressive multiple sclerosis (ACTiMuS): study protocol for a randomised controlled trial. Trials. 2015;16:463.
  24. Rice C et al. Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II). BMJ Open. 2015;5:e009090.
  25. Uccelli A, MESEMS study group. et al. MEsenchymal StEm cells for multiple sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019;20:263.

Patient's results of treatment
at Swiss Medica

Parkinson's disease
Autism
Lyme disease
Dementia
Multiple Sclerosis
Osteoarthritis
Diabetes type 2
Alzheimer
Kidney Disease

And what results can you get from stem cell treatment?

Fill out the form to discuss the disease and treatment options with an expert! You'll be contacted by our Medical Advisor who will collect information (medical reports, etc.) for the doctor and answer your basic questions:

1. Whether stem cell therapy will be effective in your specific case.

2. What the treatment involves.

3. How much does it cost.

CONTACT
your Medical Advisor
Please fill in all required fields.

About Swiss Medica clinic

Our primary task is to make your own cells treat your own body. We use advanced technology to activate mesenchymal stem cells derived from adipose tissue, bone marrow, etc. Donated cells can also be used. Introduced to the patient’s body, these cells help to regenerate damaged tissue. Symptoms become less obvious and/or disappear.

Follow Us

Disclaimer

*Patient feedback, articles and testimonials provided on this site are for informational purposes only and should not be considered as a guaranteed result for every case of illness. The treatment result depends on the disease, patient’s condition, number of treatment procedures, etc.

All form fields are required.